Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-09-06 08:31 am Purchase |
2024-09-06 | 13D | Gyre Therapeutics, Inc. GYRE |
Ma Songjiang | 7,456,847 7.620% |
7,456,847 (New Position) |
Filing History |
| 2024-09-06 08:15 am Purchase |
2024-09-06 | 13D | Gyre Therapeutics, Inc. GYRE |
Luo Ying | 8,458,983 8.540% |
8,458,983 (New Position) |
Filing History |
| 2024-02-14 1:18 pm Unchanged |
2023-12-31 | 13G | Gyre Therapeutics, Inc. GYRE |
LYTTON LAURENCE W | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2024-01-24 5:11 pm Unchanged |
2024-01-22 | 13D | Gyre Therapeutics, Inc. GYRE |
GNI Group Ltd. | 73,313,885 85.340% |
0 (Unchanged) |
Filing History |
| 2023-11-27 4:49 pm Unchanged |
2023-11-22 | 13D | Gyre Therapeutics, Inc. GYRE |
GNI Group Ltd. | 73,313,885 85.360% |
0 (Unchanged) |
Filing History |
| 2023-11-01 4:58 pm Purchase |
2023-10-30 | 13D | Gyre Therapeutics, Inc. GYRE |
GNI Group Ltd. | 73,313,885 85.360% |
73,313,885 (New Position) |
Filing History |
| 2023-10-30 7:28 pm Unchanged |
2023-10-27 | 13D | Catalyst Biosciences, Inc. CBIO |
GNI Group Ltd. | 417,768 16.500% |
0 (Unchanged) |
Filing History |
| 2023-02-14 4:46 pm Sale |
2022-12-31 | 13G | Catalyst Biosciences, Inc. CBIO |
Nantahala Capital Management, LLC | 29,204 1.400% |
-670,969 (-95.83%) |
Filing History |
| 2023-02-14 4:09 pm Sale |
2022-12-31 | 13G | Catalyst Biosciences, Inc. CBIO |
ORBIMED ADVISORS LLC | 0 0.000% |
-342,423 (Position Closed) |
Filing History |
| 2023-02-13 2:55 pm Sale |
2022-12-31 | 13G | Catalyst Biosciences, Inc. CBIO |
LYTTON LAURENCE W | 177,822 7.100% |
-294,793 (-62.37%) |
Filing History |
| 2023-02-13 12:06 pm Sale |
2022-12-30 | 13G | Catalyst Biosciences, Inc. CBIO |
Renaissance Technologies LLC | 79,132 3.140% |
-370,105 (-82.39%) |
Filing History |
| 2023-01-04 6:13 pm Purchase |
2022-12-26 | 13D | Catalyst Biosciences, Inc. CBIO |
GNI Group Ltd. | 417,768 16.600% |
417,768 (New Position) |
Filing History |
| 2022-10-07 07:45 am Sale |
2022-10-04 | 13D | Catalyst Biosciences, Inc. CBIO |
SINGER JULIAN D. | 72,160 3.440% |
-497,641 (-87.34%) |
Filing History |
| 2022-09-22 4:15 pm Sale |
2022-09-21 | 13D | Catalyst Biosciences, Inc. CBIO |
JEC II Associates LLC | 0 0.000% |
-635,101 (Position Closed) |
Filing History |
| 2022-08-19 4:30 pm Unchanged |
2022-08-18 | 13D | Catalyst Biosciences, Inc. CBIO |
SINGER JULIAN D. | 569,801 7.100% |
0 (Unchanged) |
Filing History |
| 2022-08-03 4:17 pm Unchanged |
2022-08-03 | 13D | Catalyst Biosciences, Inc. CBIO |
SINGER JULIAN D. | 569,801 7.100% |
0 (Unchanged) |
Filing History |
| 2022-08-01 4:15 pm Unchanged |
2022-07-31 | 13D | Catalyst Biosciences, Inc. CBIO |
JEC II Associates LLC | 635,101 8.000% |
0 (Unchanged) |
Filing History |
| 2022-07-22 2:21 pm Purchase |
2022-07-20 | 13D | Catalyst Biosciences, Inc. CBIO |
SINGER JULIAN D. | 569,801 7.100% |
58,974 (+11.54%) |
Filing History |
| 2022-07-01 4:15 pm Unchanged |
2022-06-29 | 13D | Catalyst Biosciences, Inc. CBIO |
JEC II Associates LLC | 635,101 8.000% |
0 (Unchanged) |
Filing History |
| 2022-06-21 5:02 pm Purchase |
2022-06-13 | 13D | Catalyst Biosciences, Inc. CBIO |
JEC II Associates LLC | 635,101 8.000% |
635,101 (New Position) |
Filing History |